tbuckley/cabot-search huggingface dataset:
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)
Authors: T. Powles, R.J. Motzer, D.J. George, E. Jonasch, S. Pal, N.M. Tannir, S. Signoretti, T.H. Mai, C. Scheffold, E. Wang, D.T. Aftab, B. Escudier, T.K. Choueiri
Journal: Annals of Oncology (2017)
Clinicopathologic features and long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (≥ 5 years) to frontline imatinib (IM): A case-control study from GEIS
Authors: C. Serrano, A. Lopez Pousa, I. Pajares, C. Valverde Morales, J. Duran, J. Rubió-Casadevall, M.J. Safont, V. Martinez, R. Díaz Beveridge, A. Estival, D. Vicente Baz, A. Sebio Garcia, N. Hindi, S. Landolfi, D. Olivares, A. Garcia-Valverde, P. Ledesma, J. Arribas, J. Carles Galceran, J. Martin Broto
Journal: Annals of Oncology (2017)
Staging and assessment of the response to PET-CT treatment in non-small cell lung carcinoma
Authors: M. Mendez Garcia, M.A. Brenes, R. Gómez, M. Soriano, M. Torrente, C. Maximiano, G. Díaz, B. Rodríguez, M.D.M. Córdoba, M. Provencio Pulla
Journal: Annals of Oncology (2017)
Germline Mutations in Patients Receiving Unrelated Donor Hematopoietic Cell Transplant for Severe Aplastic Anemia
Authors: Shahinaz M. Gadalla, Bari J Ballew, Michael D Haagenson, Stephen R. Spellman, Belynda Hicks, Blanche P Alter, Bin Zhu, Weiyin Zhou, Meredith Yeager, Tao Wang, Katharina Fleischhauer, Katharine C. Hsu, Michael R. Verneris, Neal Freedman, Stephanie J. Lee, Sharon A Savage
Journal: Blood (2016)
Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus
Authors: Lei Xu, Yin Li, Xianben Liu, Haibo Sun, Ruixiang Zhang, Jianbo Zhang, Yan Zheng, Zongfei Wang, Shilei Liu, Xiankai Chen
Journal: Journal of Thoracic Oncology (2017)
Risk factors for febrile neutropenia (FN) in unresectable/recurrent pancreatic cancer(PC) patients(pts) receiving FOLFIRINOX (FFX) from JASPAC06 study
Authors: M. Sasaki, H. Ueno, K. Omae, T. Goto, G. Murohisa, N. Mizuno, M. Ozaka, S. Kobayashi, K. Uesugi, N. Kobayashi, H. Hayashi, K. Sudo, N. Okano, Y. Horita, K. Kamei, T. Hosokawa, T. Henmi, M. Kobayashi, A. Todaka, A. Fukutomi
Journal: Annals of Oncology (2017)
Real world data of practice patterns and outcomes for pemetrexed plus platinum as neoadjuvant chemotherapy in adenocarcinomas of lung from a tertiary cancer center of India: Looking beyond the usual paradigm
Authors: A. Kapoor, S. Zanwar, A. Joshi, V. Noronha, V. Patil, A. Chougule, A. Mahajan, P. Bhargava, K. Prabhash
Journal: Annals of Oncology (2017)
Comparison of platinum agents cisplatin and carboplatin in routine treatment of advanced NSCLC: Results from prospective German TLK cohort study
Authors: N. Marschner, U. von Verschuer, R. Schnell, M-O. Zahn, J. Eggert, A. Binninger, L. Spring, M. Jänicke
Journal: Annals of Oncology (2017)
Résultats d’une enquête européenne pour évaluer la présence d’un nouveau variant de Chlamydia trachomatis
Authors: E J Savage, C Ison, M Jw Van de Laar
Journal: Eurosurveillance (2007)

Un nouveau variant de Chlamydia trachomatis a ete signale en Suede en 2006. Trois pays (Irlande, Norvege et Danemark) ont a ce jour detecte ce variant, mais le nombre de cas reste encore tres limite.
Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037
Authors: O. Hamid, T.F. Gajewski, A.E. Frankel, T.M. Bauer, A.J. Olszanski, J.J. Luke, A.S. Balmanoukian, E.V. Schmidt, B. Sharkey, J. Maleski, M.J. Jones, T.C. Gangadhar
Journal: Annals of Oncology (2017)
Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC)
Authors: H. Woopen, P. Wimberger, A. Mustea, G. Oskay-Oezcelik, M. Keller, R. Richter, J. Harde, S. Klawitter, A. Wegenaer, O. Tomé, J. Sehouli
Journal: Annals of Oncology (2017)
Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK and ROS-1 versus next-generation sequence (NGS) in advanced adenocarcinoma lung cancer patients.
Authors: Luciene Schluckebier, Rosangela Caetano, Veronica Aran, Carlos G. M. Ferreira
Journal: Journal of Clinical Oncology (2017)

9068 Background: Success of a target therapy is directly correlated with the accuracy of its companion diagnostic test. Without a corresponding biomarker, target therapy may yield shorter survival, waste time, increase burdens and costs. As important as conducting cost-effectiveness studies for therapies, it is also valuable to compare different molecular tests. In lung cancer, the mutational status of EGFR and translocation of ALK and ROS-1 are commonly tested to offer the best intervention. Our objective is to evaluate the cost-effectiveness of a unique exam using NGS versus other routinely used tests such as the ones which involve RT-PCR and FISH. Methods: Target population is NSCLC, adenocarcinoma, and candidates to first-line therapy. Strategy 1: test EGFR mutation if EGFR test is negative, individual follow to FISH for ALK; if FISH is negative, follow to FISH for ROS-1. Strategy 2: differs from 1 since FISH for ALK and ROS are requested together. Strategy 3: all individuals are submitted to NGS (multicomplex platform which include EGFR, ALK, ROS-1 and other genes). Tests could also be classified as unknown due to the quality of tumor sample. Prevalence of biomarker, test accuracy and proportion of unknown results were used to calculate each decision tree branch. Sensitivity and specificity was obtained from literature review using Sanger as reference standard for RT-PCR tests and NGS. The study was analyzed from a healthcare-payer perspective based on Brazilian private sector. Costs were based on data from diagnostic companies, ANS and AMB-CBHPM 2016. Results: The use of NGS added 24% extra cases correct identified as well as extra costs (US$ 800.76; PPP 2015) attributed to the molecular testing. The ICER comparing NGS with sequential tests was US$ 3,381.82/correct case detected. Comparing strategy 2:1, the ICER was US$937.86/correct case detected. Conclusions: this study is part of an effort to integrate companion diagnostics discussions on precision medicine and covered drugs in the Brazilian health system. These findings can also subsidy cost-effectiveness studies that incorporates subsequent treatments and survival.
The role of clinical characteristics in low grade gliomas in molecular era
Authors: A. Mura, E. Franceschi, S. Minichillo, A. Mandrioli, A. Tosoni, A. Fioravanti, A. Talacchi, L. Volpin, G. Tallini, D. De Biase, R. Agati, S. Pizzolitto, S. Bartolini, A. Paccapelo, A.A. Brandes
Journal: Annals of Oncology (2017)
Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study
Authors: M. Ruiz-Borrego, M. Martin Jimenez, A. Ruiz, A. Lluch, M. Ramos, J. Cruz Jurado, J.M. Baena-Canada, B. Cirauqui, A. Rodriguez-Lescure, E. Alba Conejo, N. Martínez Jañez, M. Muñoz, S. Antolin, I. Álvarez López, S. Del Barco, L. Garcia-Estevez, J.I. Chacon Lopez-Muniz, A. Anton Torres, E. Carrasco
Journal: Annals of Oncology (2017)
Marcato declino della pertosse in seguito alla reintroduzione della vaccinazione contro la pertosse in Svezia
Authors: P Olin, H O Hallander
Journal: Eurosurveillance (1999)

La vaccinazione contro la pertosse, con un vaccino acellulare per bambini, a tre, cinque e 12 mesi d'eta e entrata a far parte del programma di vaccinazione svedese nel Gennaio 1996, 17 anni dopo il ritiro del vaccino a cellula intera avvenuto nel 1979 (1). In alcuni mesi la copertura ha raggiunto almeno il 95%, prevalentemente mediante la somministrazione di un vaccino a tre componenti incluso nel vaccino trivalente contro difterite, pertosse e tetano (DPT). In alcune zone, ai bambini in eta prescolare piu grandi, e stato dato esclusivamente il vaccino contro la pertosse acellulare a tre componenti e in una zona (Gothenburg e dintorni), nell'ambito di uno studio clinico, e stata effettuata una campagna di reclutamento, utilizzando esclusivamente un vaccino contro la pertosse a componente unica (2).
Corrigendum to “Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension” [J Hepatol 62 (2015) 325–331]
Authors: Rajeshwar P. Mookerjee, Gautam Mehta, Vairappan Balasubramaniyan, Fatma El Zahraa Mohamed, Nathan Davies, Vikram Sharma, Yasuko Iwakiri, Rajiv Jalan
Journal: Journal of Hepatology (2017)
A phase II study with lead-in safety cohort of cabazitaxel (C) plus lapatinib (L) as therapy for HER2+ metastatic breast cancer (MBC) with intracranial metastases (mets).
Authors: Denise A. Yardley, John D. Hainsworth, Erika Paige Hamilton, Lowell L. Hart, Mythili Shastry, Laura M. DeBusk, Howard A. Burris
Journal: Journal of Clinical Oncology (2014)

TPS667 Background: Although HER2-targeted therapy has improved outcomes in HER2+ breast cancer (BC) patients (pts), CNS mets continue to be a significant source of morbidity and mortality. Inability of drugs like trastuzumab to cross the blood-brain barrier (BBB) renders the CNS a sanctuary site for mets. L is a small molecule tyrosine kinase EGFR1/HER2 inhibitor that crosses the BBB and is active against CNS mets. C is a new taxane approved for prostate cancer that is also active in taxane-resistant metastatic breast cancer (MBC) and distinguishes itself by its ability to cross the BBB. The activity shown by C in taxane-resistant MBC as well as the CNS penetrance of both C and L make this an attractive combination for HER2+ MBC pts with CNS mets. Methods: This is an open-label, non-randomized, phase II study with a lead-in safety cohort (NCT01934894). Pts ≥ 18 yrs with HER2+ (by FISH or IHC 3+) MBC and CNS mets are eligible. Patients must have either at least 1 untreated measurable CNS lesion ≥ 5mm in longest dimension on MRI or at least 1 previously treated (by WBRT and or/SRS) CNS lesion with evidence of intra-cranial disease progression following WBRT or SRS. Pts must have had at least 1 prior HER2 therapy; first line MBC pts are eligible only if they progressed during or within 6 mos of adjuvant therapy. Prior treatment (tx) with C is not permitted. During the lead-in, cohorts of 3 pts will be treated with escalating doses of q 3 weeks (wks) C and daily L to determine the tolerability and optimal dose. Subsequent pts will be treated with the identified optimal dose combination. Each tx cycle is 3 wks and systemic and intra-cranial disease restaging will occur every 2 cycles for the first 8 cycles and then every 3 cycles until PD or unacceptable toxicity. The primary study objectives are to determine the safety and CNS ORR (ORR=CR+PR) of the combination of C and L in HER2+ MBC pts. Secondary objectives include evaluation of the clinical benefit rate ([CBR]CR+PR+SD ≥ 6 mos), 3- and 6-mo PFS rate for CNS mets, and response rate and CBR for extra-cranial mets. The trial is ongoing. Clinical trial information: NCT01934894.
Evidence of <i>PIK3CA</i> and <i>TP53</i> co-mutation in breast cancer identification on next-generation sequencing (NGS) of <i>ERBB2</i> (<i>HER2</i>)-amplified residual disease following preoperative anti-HER2 therapy.
Authors: Frankie Ann Holmes, Kai Wang, Maren K. Levin, Ying Cao, Gary A. Palmer, Norma Alonzo Palma, Sohail Balasubramanian, Jeffrey S. Ross, Roman Yelensky, Lea Krekow, Kristi McIntyre, Cynthia R. C. Osborne, Joyce O'Shaughnessy
Journal: Journal of Clinical Oncology (2014)

625 Background: Understanding the molecular alterations in residual, treatment-refractory HER2-positive breast cancer (BC) following preoperative trastuzumab (H), lapatinib (L) or both (HL) in combination with chemotherapy may help identify patients at risk for not achieving pathologic complete responses as well as genomic alterations (GA) to target to overcome therapy resistance. Here we summarize the GA present in 21 pts’ residual BC following preoperative anti-HER2 therapy. Methods: 100 pts with stage 2/3 HER2+ BC were randomized to treatment with H vs L 1250mg vs HL (L 750-1000mg) along with preoperative 5-fluoruracil, epirubicin, cyclophosphamide followed by weekly paclitaxel (Holmes F. BMC Res Notes 6:507, 2013). Following IRB-approved informed consent, targeted NGS was performed on 21 pts’ FFPE residual disease (RD) after preoperative therapy at a CLIA-certified laboratory to characterize all classes of genomic alterations across 287 cancer-related genes. Results: 3 of 21 pts with RD were HER2-negative (1 with TP53 mutation and EGFR amplification; 1 with PIK3CA mutation). Of the 18 HER2+ RD (5 ER- and 13 ER+), 13 (72%) had TP53 mutations; 8 (44%) had PIK3CA mutations, always co-mutated with TP53 (3 ER- and 5 ER+). Although prevalence of TP53 and PIK3CA mutation was only modestly higher than published estimates for HER2+ primary BC (55% and 32% for TP53 and PIK3CA, respectively - Stephens P. Nature 486:400, 2012), prevalence of co-mutations appeared significantly higher – 44% vs. 18%, p<0.1). Of the 4 RD post-HL, 3 were ER+, all had TP53 mutations, 2 with PIK3CA mutations. Other prevalent alterations in checkpoint-related genes included truncations in ATM and BRCA1, and amplification of EMSY, MDM2 and MDM4. Ampifications of CCND1 and CDK4 were also present. Conclusions: The enrichment of PIK3CA and TP53 co-mutations in BC pts’ HER2-amplifed RD following preoperative H or L or HL plus chemotherapy may predict for high sensitivity to PI3K inhibitors (Kim N, Int J Cancer 131:2456, 2012; Daemen A. Genome Biol 14:R110, 2013), and provides evidence for potentially actionable targeted treatment.
Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies
Authors: J. Tsurutani, T. Doi, H. Iwata, S. Takahashi, S. Modi, K. Tamura, K. Shitara, H. Taniguchi, S. Taira, B. Li, A. Shimomura, Y. Sato, K. Akiyama, Y. Fujisaki, C. Lee, A. Yver, K. Nakagawa
Journal: Annals of Oncology (2017)
A secondary case of meningococcal disease in an ambulance worker, Berkshire, November 2007
Authors: A Petsas, A Sharma, O Aghadiuno, M Abid, K Paranthaman
Journal: Eurosurveillance (2008)

Secondary cases of meningococcal disease among healthcare workers are rare and avoidable. In this report, we describe a secondary infection in a healthcare worker who did not have significant contact with respiratory secretions of the index case.
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Authors: Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel
Journal: Circulation (2005)

It is important that the medical profession play a significant role in critically evaluating the use of diagnostic procedures and therapies as they are introduced and tested in the detection, management, or prevention of disease states.Rigorous and expert analysis of the available data documenting relative benefits and risks of those procedures and therapies can produce helpful guidelines that improve the effectiveness of care, optimize patient outcomes, and favorably affect the overall cost of care by focusing resources on the most effective strategies.The American College of Cardiology (ACC) and the American Heart Association (AHA) have jointly engaged in the production of such guidelines in the area of cardiovascular disease since 1980.This effort is directed by the ACC/AHA Task Force on Practice Guidelines, whose charge is to develop and revise practice guidelines for important cardiovascular diseases and procedures.Experts in the subject under consideration are selected from both organizations and charged with examining subject-specific data and writing or updating these guidelines.The process includes additional representatives from other medical practitioner and specialty groups where appropriate.Writing groups are specifically charged to perform a formal literature review, weigh the strength of evidence for or against a particular treatment or procedure, and include estimates of expected health outcomes where data exist.Patient-specific modifiers, comorbidities, and issues of patient preference that might influence the choice of particular tests or therapies are considered, as are frequency of follow-up and cost-effectiveness.When available, information from studies on cost will be considered; however, review of data on efficacy and clinical out-e156
Kidney Proximal Tubule Lipoapoptosis Is Regulated by Fatty Acid Transporter-2 (FATP2)
Authors: Shenaz Khan, Pablo D. Cabral, William P. Schilling, Zachary W. Schmidt, Asif N. Uddin, Amelia Gingras, Sethu M. Madhavan, Jeffrey L. Garvin, Jeffrey R. Schelling
Journal: Journal of the American Society of Nephrology (2017)

Albuminuria and tubular atrophy are among the highest risks for CKD progression to ESRD. A parsimonious mechanism involves leakage of albumin-bound nonesterified fatty acids (NEFAs) across the damaged glomerular filtration barrier and subsequent reabsorption by the downstream proximal tubule, causing lipoapoptosis. We sought to identify the apical proximal tubule transporter that mediates NEFA uptake and cytotoxicity. We observed transporter-mediated uptake of fluorescently labeled NEFA in cultured proximal tubule cells and microperfused rat proximal tubules, with greater uptake from the apical surface than from the basolateral surface. Protein and mRNA expression analyses revealed that kidney proximal tubules express transmembrane fatty acid transporter-2 (FATP2), encoded by Slc27a2, but not the other candidate transporters CD36 and free fatty acid receptor 1. Kidney FATP2 localized exclusively to proximal tubule epithelial cells along the apical but not the basolateral membrane. Treatment of mice with lipidated albumin to induce proteinuria caused a decrease in the proportion of tubular epithelial cells and an increase in the proportion of interstitial space in kidneys from wild-type but not Slc27a2-/- mice. Ex vivo microperfusion and in vitro experiments with NEFA-bound albumin at concentrations that mimic apical proximal tubule exposure during glomerular injury revealed significantly reduced NEFA uptake and palmitate-induced apoptosis in microperfused Slc27a2-/- proximal tubules and Slc27a2-/- or FATP2 shRNA-treated proximal tubule cell lines compared with wild-type or scrambled oligonucleotide-treated cells, respectively. We conclude that FATP2 is a major apical proximal tubule NEFA transporter that regulates lipoapoptosis and may be an amenable target for the prevention of CKD progression.
GW28-e1063 Effectiveness of single-stenting in patients with left main coronary artery lesions
Authors: Xuebin Wang, Liangping Zhao, Biao Yao, Yuqi Chen, Mousong Wang, Xianyuan Luo, Weiting Xu, Jianchang Chen, Liangping Zhao
Journal: Journal of the American College of Cardiology (2017)
NY-ESO-1 antigen expression as a prognostic factor for soft tissue sarcomas.
Authors: Yuriy Komarov, Anton Barchuk, Anna Igorevna Semenova, Tatiana Semiglazova, Evgenii Imianitov, Aglaya Iyevleva, Irina Baldueva, Alexey Viktorovich Novik, Tatyana Leonidovna Nehaeva, Nino Pipia, Heini Huhtala, Alexander Ivantsov, Anna Artemyeva, Malcolm Moore, Svetlana Protsenko
Journal: Journal of Clinical Oncology (2017)

11075 Background: While a number of antigens are known to be expressed in soft tissue sarcomas, little is known about the prognosis of patients with such tumors. Recent data have demonstrated immunologic activity in sarcoma patients expressing the NY-ESO antigen, found positive in 20-80% cases. MAGE A3 has also recently attracted attention with regard to soft tissue sarcomas. In our study we aimed to assess any association between antigen expression and prognosis. Methods: In a case-control study we retrospectively collected data from a prospective database of all 137 patients with sarcomas receiving first line therapy in the Petrov Research Institute of Oncology in Saint-Petersburg. All cases were morphologically verified, with mRNA expression of NY-ESO-1, MAGE A3, PDGFR A, PDGFR B, beta-tubullin and top2alpha additionally being tested by quantitative real-time PCR in a subset of patients. The log-rank test was applied to compare Kaplan-Mayer estimates of progression-free (PFS) and overall survival (OS) by univariate analysis. Hazard ratios were derived after adjustment for age, gender, several covariates for type of chemotherapy and disease stage with two-sided probability at a significance level of 0.05. Results: The positive rate for expression of NY-ESO was 20% (11/43).Only NY-ESO was significantly associated with PFS (p &lt; 0,001), with a median durations of 10, 4 and 7 months for positive, negative and not tested for NY-ESO expression, respectively. The adjusted hazard ratio (HR) for NY-ESO positive patients was 2.2 (95%CI, 1.2;4.2) compared with their negative counterparts, The HR for patients not tested for NY-ESO was 2.0 (95%CI, 1.3;3.0). Among other covariates, only a combination of drugs was associated with a lower risk of progression (HR, 0.7 95%CI, 0.4;0.98) , as compared to those receiving a single chemotherapy agent. Conclusions: This first report showing prognostic significance of NY-ESO expression in soft tissue sarcoma patients, suggests that research should be focused on targeting this antigen. Participation in clinical trials for patients with positive NY-ESO expression is highly recommended, because of poor survival regardless of the type of standard treatment.
Prognostic factors and specific populations in the pharmacogenetic randomized phase II trial of FOLFIRI with high-dose (HD) of irinotecan vs standard doses in metastatic colorectal cancer (mCRC) patients (pts) according to UGT1A1 genotype
Authors: M. Tobeña, D. Paez, A. Sebio Garcia, J. Fernandez-Plana, M. Martín, A. Virgili, L. Cirera, P. Riera, I. Sullivan, J. Salazar
Journal: Annals of Oncology (2017)
Do patients over 70 years with advanced head and neck squamous cell carcinoma tolerate curative intent concurrent chemo-radiation? Predictors of oncological outcomes
Authors: V. Srinivasalu, N. Subramaniam, N. Kumar, D. Balasubramaniam, A. Philip, A. Susan, A. Remesan Nair, C. G Prameela, K.U. Pushpaja, K. Thankappan, W. Jose, S. Iyer, P. Keechilat
Journal: Annals of Oncology (2017)